Cancer clinical trials in the region Occitanie

174 currently recruiting clinical trials
Region Occitanie

Phase 2 Lung cancer
#NCT04995523
NSCLC (Non-Small Cell Lung Cancer) Metastatic 1 2 3 or more
Immunotherapy
5 main criterias to confirm
Centre Hospitalier Universitaire de Toulouse (Toulouse)
AstraZeneca
Phase 2 Lung cancer
#NCT04995523
NSCLC (Non-Small Cell Lung Cancer) Locally Advanced Metastatic Immunotherapy 1 2 3 or more
5 main criterias to confirm
Centre Hospitalier Universitaire de Toulouse (Toulouse)
AstraZeneca
Phase 2 Colon cancer Rectal cancer Anal cancer Pancreas cancer
#NCT06162221
Locally Advanced Metastatic KRAS G12C
Systemic Treatment-Naive Systemic Treatment-Naive
5 main criterias to confirm
IUCT Oncopôle (Toulouse)
Revolution Medicines, Inc.
Phase 2 Lymphoma
#NCT06271057
B cell lymphoma Large B cell lymphoma Primary mediastinal lymphoma Indolent transformed lymphoma > 60 ml/min 2 3 or more
Systemic Treatment-Naive
6 main criterias to confirm
IUCT Oncopôle (Toulouse), Centre Hospitalier Universitaire de Montpellier - Site Arnaud de Villeneuve (Montpellier)
Organisation de recherche universitaire sur le lymphome
Phase 2 Liver and bile duct cancer
#NCT05622071
Hepatocellular carcinoma Unhealthy B B C
Transplant Immunotherapy
7 main criterias to confirm
Centre Hospitalier Universitaire de Montpellier - Site de Saint Eloi (Montpellier)
UNICANCER
Phase 2 Colon cancer Rectal cancer
#NCT04956640
Locally Advanced Metastatic KRAS G12C Chemotherapy
4 main criterias to confirm
IUCT Oncopôle (Toulouse), Institut du cancer de Montpellier (Montpellier)
Eli Lilly et compagnie
Phase 2 Pancreas cancer
#NCT04956640
Adenocarcinoma Locally Advanced Metastatic KRAS G12C
4 main criterias to confirm
IUCT Oncopôle (Toulouse), Institut du cancer de Montpellier (Montpellier)
Eli Lilly et compagnie
Phase 2 Lymphoma
#NCT05283720
B cell lymphoma Mantel cell lymphoma CD20 None 1 2 3 or more
Bispecific T-cell engager antibodies
6 main criterias to confirm
IUCT Oncopôle (Toulouse)
Abbvie
Phase 2 Lymphoma
#NCT05283720
B cell lymphoma Follicular lymphoma CD20 1 2 3 or more
Systemic Treatment-Naive Bispecific T-cell engager antibodies
6 main criterias to confirm
IUCT Oncopôle (Toulouse)
Abbvie
Phase 2 Lymphoma
#NCT05283720
B cell lymphoma Large B cell lymphoma Indolent transformed lymphoma CD20 None 1 2 3 or more
Bispecific T-cell engager antibodies
6 main criterias to confirm
IUCT Oncopôle (Toulouse)
Abbvie